Src and CXCR4 are involved in the invasiveness of breast cancer cells with acquired resistance to lapatinib

Cell Cycle

Volumn 13, Issue 1, 2014, Pages 148-156

  De Luca, Antonella ^a   D'Alessio, Amelia ^a   Gallo, Marianna ^a   Maiello, Monica R ^a   Bode, Ann M ^b   Normanno, Nicola ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Breast cancer; CXCR4; ErbB 2; Lapatinib; Resistance; Saracatinib; Src kinase

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; EPIDERMAL GROWTH FACTOR RECEPTOR 2; LAPATINIB; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE B; PROTEIN TYROSINE KINASE; SARACATINIB;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER PATIENT; CANCER RESISTANCE; CELL MEMBRANE; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME INHIBITION; EXTRACELLULAR MATRIX; GROWTH RATE; HUMAN; HUMAN CELL; IC 50; PHENOTYPE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR INVASION;

BREAST CANCER; CXCR4; ERBB-2; LAPATINIB; RESISTANCE; SARACATINIB; SRC KINASE;

BREAST NEOPLASMS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASM INVASIVENESS; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, ERBB-2; RECEPTORS, CXCR4; SIGNAL TRANSDUCTION; SRC-FAMILY KINASES;

EID: 84892611820     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.26899     Document Type: Article

References (42)

1. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235:177-82; PMID:3798106; http://dx.doi.org/ 10.1126/science.3798106 (Pubitemid 17231334)
2. Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, et al. Molecular portraits of human breast tumours. Nature 2000; 406: 747-52; PMID:10963602; http://dx.doi.org/10. 1038/35021093
3. Normanno N, Morabito A, De Luca A, Piccirillo MC, Gallo M, Maiello MR, Perrone F. Target-based therapies in breast cancer: current status and future perspectives. Endocr Relat Cancer 2009; 16:675-702; PMID:19525314; http://dx.doi.org/10.1677/ERC-08-0208
4. Spector NL, Blackwell KL. Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 2009; 27: 5838-47; PMID:19884552; http://dx.doi.org/10.1200/JCO.2009. 22.1507
5. Rexer BN, Arteaga CL. Intrinsic and acquired resistance to HER2-targeted therapies in HER2 gene-amplified breast cancer: mechanisms and clinical implications. Crit Rev Oncog 2012; 17:1-16; PMID:22471661; http://dx.doi.org/10. 1615/CritRevOncog.v17.i1.20
6. Cufí S, Vazquez-Martin A, Oliveras-Ferraros C, Corominas-Faja B, Urruticoechea A, Martin-Castillo B, Menendez JA. Autophagy-related gene 12 (ATG12) is a novel determinant of primary resistance to HER2-targeted therapies: utility of transcriptome analysis of the autophagy interactome to guide breast cancer treatment. Oncotarget 2012; 3: 1600-14; PMID:23307622
7. Xia W, Mullin RJ, Keith BR, Liu LH, Ma H, Rusnak DW, Owens G, Alligood KJ, Spector NL. Antitumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways. Oncogene 2002; 21: 6255-63; PMID:12214266; http://dx.doi.org/10.1038/sj.onc. 1205794
8. Rusnak DW, Affleck K, Cockerill SG, Stubberfield C, Harris R, Page M, Smith KJ, Guntrip SB, Carter MC, Shaw RJ, et al. The characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors: potential therapy for cancer. Cancer Res 2001; 61: 7196-203; PMID:11585755 (Pubitemid 32946515)
9. Tang L, Wang Y, Strom A, Gustafsson JA, Guan X. Lapatinib induces p27(Kip1)-dependent G1 arrest through both transcriptional and post-translational mechanisms. Cell Cycle 2013; 12:2665-74; PMID:23907131; http://dx.doi.org/10.4161/cc.25728
10. D'Alessio A, De Luca A, Maiello MR, Lamura L, Rachiglio AM, Napolitano M, Gallo M, Normanno N. Effects of the combined blockade of EGFR and ErbB-2 on signal transduction and regulation of cell cycle regulatory proteins in breast cancer cells. Breast Cancer Res Treat 2010; 123: 387-96; PMID:19946741; http://dx.doi.org/10.1007/s10549-009-0649-x
11. Konecny GE, Pegram MD, Venkatesan N, Finn R, Yang G, Rahmeh M, Untch M, Rusnak DW, Spehar G, Mullin RJ, et al. Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res 2006; 66: 1630-9; PMID:16452222; http://dx.doi.org/10. 1158/0008-5472.CAN-05-1182 (Pubitemid 43259947)
12. Scaltriti M, Rojo F, Ocaña A, Anido J, Guzman M, Cortes J, Di Cosimo S, Matias-Guiu X, Ramon y Cajal S, Arribas J, et al. Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. J Natl Cancer Inst 2007; 99: 628-38; PMID:17440164; http://dx.doi.org/10.1093/jnci/djk134 (Pubitemid 47073544)
13. Nahta R, Yuan LX, Du Y, Esteva FJ. Lapatinib induces apoptosis in trastuzumab-resistant breast cancer cells: effects on insulin-like growth factor I signaling. Mol Cancer Ther 2007; 6: 667-74; PMID:17308062; http://dx.doi.org/10.1158/1535-7163.MCT-06-0423 (Pubitemid 46332467)
14. Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T, Jagiello-Gruszfeld A, Crown J, Chan A, Kaufman B, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006; 355: 2733-43; PMID:17192538; http://dx.doi.org/10.1056/NEJMoa064320 (Pubitemid 46021510)
15. Xia W, Bacus S, Hegde P, Husain I, Strum J, Liu L, Paulazzo G, Lyass L, Trusk P, Hill J, et al. A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer. Proc Natl Acad Sci U S A 2006; 103: 7795-800; PMID:16682622; http://dx.doi.org/10.1073/pnas.0602468103
16. Rexer BN, Ham AJ, Rinehart C, Hill S, Granja-Ingram Nde M, González-Angulo AM, Mills GB, Dave B, Chang JC, Liebler DC, et al. Phosphoproteomic mass spectrometry profiling links Src family kinases to escape from HER2 tyrosine kinase inhibition. Oncogene 2011; 30:4163-74; PMID:21499296; http://dx.doi.org/10.1038/onc.2011.130
17. Huang C, Park CC, Hilsenbeck SG, Ward R, Rimawi MF, Wang YC, Shou J, Bissell MJ, Osborne CK, Schiff R. β1 integrin mediates an alternative survival pathway in breast cancer cells resistant to lapatinib. Breast Cancer Res 2011; 13:R84; PMID:21884573; http://dx.doi.org/10.1186/bcr2936
18. Liu L, Greger J, Shi H, Liu Y, Greshock J, Annan R, Halsey W, Sathe GM, Martin AM, Gilmer TM. Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells: activation of AXL. Cancer Res 2009; 69: 6871-8; PMID:19671800; http://dx.doi.org/10.1158/0008-5472.CAN-08-4490
19. Jegg AM, Ward TM, Iorns E, Hoe N, Zhou J, Liu X, Singh S, Landgraf R, Pegram MD. PI3K independent activation of mTORC1 as a target in lapatinib-resistant ERBB2+ breast cancer cells. Breast Cancer Res Treat 2012; 136: 683-92; PMID:23089982; http://dx.doi.org/10.1007/s10549-012-2252-9
20. Xia W, Husain I, Liu L, Bacus S, Saini S, Spohn J, Pry K, Westlund R, Stein SH, Spector NL. Lapatinib antitumor activity is not dependent upon phosphatase and tensin homologue deleted on chromosome 10 in ErbB2-overexpressing breast cancers. Cancer Res 2007; 67: 1170-5; PMID:17283152; http://dx.doi.org/10.1158/0008-5472.CAN-06-2101
21. Dave B, Migliaccio I, Gutierrez MC, Wu MF, Chamness GC, Wong H, Narasanna A, Chakrabarty A, Hilsenbeck SG, Huang J, et al. Loss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2-overexpressing locally advanced breast cancers. J Clin Oncol 2011; 29: 166-73; PMID:21135276; http://dx.doi.org/10.1200/JCO.2009.27.7814
22. Valabrega G, Capellero S, Cavalloni G, Zaccarello G, Petrelli A, Migliardi G, Milani A, Peraldo-Neia C, Gammaitoni L, Sapino A, et al. HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib. Breast Cancer Res Treat 2011; 130: 29-40; PMID:21153051; http://dx.doi.org/10.1007/s10549-010-1281-5
23. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, Lindeman N, Gale CM, Zhao X, Christensen J, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007; 316:1039-43; PMID:17463250; http://dx.doi.org/10.1126/science.1141478 (Pubitemid 46799492)
24. De Luca A, Normanno N. Predictive biomarkers to tyrosine kinase inhibitors for the epidermal growth factor receptor in non-small-cell lung cancer. Curr Drug Targets 2010; 11: 851-64; PMID:20388064; http://dx.doi.org/10. 2174/138945010791320773
25. Li J, Zhu F, Lubet RA, De Luca A, Grubbs C, Ericson ME, D'Alessio A, Normanno N, Dong Z, Bode AM. Quercetin-3-methyl ether inhibits lapatinibsensitive and -resistant breast cancer cell growth by inducing G(2)/M arrest and apoptosis. Mol Carcinog 2013; 52: 134-43; PMID:22086611; http://dx.doi.org/10.1002/mc.21839
26. Zhang S, Huang WC, Li P, Guo H, Poh SB, Brady SW, Xiong Y, Tseng LM, Li SH, Ding Z, et al. Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways. Nat Med 2011; 17: 461-9; PMID:21399647; http://dx.doi.org/10.1038/nm.2309
27. Müller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, McClanahan T, Murphy E, Yuan W, Wagner SN, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001; 410: 50-6; PMID:11242036; http://dx.doi.org/10.1038/35065016 (Pubitemid 32225831)
28. Zhang XH, Wang Q, Gerald W, Hudis CA, Norton L, Smid M, Foekens JA, Massagué J. Latent bone metastasis in breast cancer tied to Src-dependent survival signals. Cancer Cell 2009; 16: 67-78; PMID:19573813; http://dx.doi.org/10.1016/j.ccr.2009.05.017
29. Zhang Y, Zhang B. TRAIL resistance of breast cancer cells is associated with constitutive endocytosis of death receptors 4 and 5. Mol Cancer Res 2008; 6: 1861-71; PMID:19074831; http://dx.doi.org/10.1158/1541-7786.MCR-08-0313
30. Kim LC, Song L, Haura EB. Src kinases as therapeutic targets for cancer. Nat Rev Clin Oncol 2009; 6:587-95; PMID:19787002; http://dx.doi.org/10.1038/ nrclinonc.2009.129
31. Saad F, Lipton A. SRC kinase inhibition: targeting bone metastases and tumor growth in prostate and breast cancer. Cancer Treat Rev 2010; 36:177-84; PMID:20015594; http://dx.doi.org/10.1016/j.ctrv.2009.11.005
32. Creedon H, Brunton VG. Src kinase inhibitors: promising cancer therapeutics? Crit Rev Oncog 2012; 17: 145-59; PMID:22471705; http://dx.doi.org/10.1615/CritRevOncog.v17.i2.20
33. Soria JC, Márk Z, Zatloukal P, Szima B, Albert I, Juhász E, Pujol JL, Kozielski J, Baker N, Smethurst D, et al. Randomized phase II study of dulanermin in combination with paclitaxel, carboplatin, and bevacizumab in advanced non-small-cell lung cancer. J Clin Oncol 2011; 29: 4442-51; PMID:22010015; http://dx.doi.org/10.1200/JCO.2011.37.2623
34. Duda DG, Kozin SV, Kirkpatrick ND, Xu L, Fukumura D, Jain RK. CXCL12 (SDF1alpha)-CXCR4/CXCR7 pathway inhibition: an emerging sensitizer for anticancer therapies? Clin Cancer Res 2011; 17: 2074-80; PMID:21349998; http://dx.doi.org/10.1158/1078-0432.CCR-10-2636
35. Xu TP, Shen H, Liu LX, Shu YQ. The impact of chemokine receptor CXCR4 on breast cancer prognosis: A meta-analysis. Cancer Epidemiol 2013
36. Domanska UM, Kruizinga RC, Nagengast WB, Timmer-Bosscha H, Huls G, de Vries EG, Walenkamp AM. A review on CXCR4/CXCL12 axis in oncology: no place to hide. Eur J Cancer 2013; 49: 219-30; PMID:22683307; http://dx.doi.org/10.1016/j. ejca.2012.05.005
37. Blagosklonny MV. Oncogenic resistance to growthlimiting conditions. Nat Rev Cancer 2002; 2: 221-5; PMID:11990858; http://dx.doi.org/10.1038/nrc743
38. Blagosklonny MV. Why therapeutic response may not prolong the life of a cancer patient: selection for oncogenic resistance. Cell Cycle 2005; 4:1693-8; PMID:16294046; http://dx.doi.org/10.4161/cc.4.12.2259 (Pubitemid 41827304)
39. Normanno N, De Luca A, Maiello MR, Campiglio M, Napolitano M, Mancino M, Carotenuto A, Viglietto G, Menard S. The MEK/MAPK pathway is involved in the resistance of breast cancer cells to the EGFR tyrosine kinase inhibitor gefitinib. J Cell Physiol 2006; 207: 420-7; PMID:16419029; http://dx.doi.org/10. 1002/jcp.20588
40. Chou TC, Talalay P. Quantitative analysis of doseeffect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984; 22: 27-55; PMID:6382953; http://dx.doi.org/10.1016/0065-2571(84)90007-4
41. De Luca A, Gallo M, Aldinucci D, Ribatti D, Lamura L, D'Alessio A, De Filippi R, Pinto A, Normanno N. Role of the EGFR ligand/receptor system in the secretion of angiogenic factors in mesenchymal stem cells. J Cell Physiol 2011; 226: 2131-8; PMID:21520065; http://dx.doi.org/10.1002/jcp.22548
42. De Luca A, Lamura L, Strizzi L, Roma C, D'Antonio A, Margaryan N, Pirozzi G, Hsu MY, Botti G, Mari E, et al. Expression and functional role of CRIPTO-1 in cutaneous melanoma. Br J Cancer 2011; 105:1030-8; PMID:21863025; http://dx.doi.org/10.1038/bjc.2011.324